Product Details
TRUXIMA- rituximab-abbs injection, solution 500mg/50mL (10mg/mL)
Manufacturer: TEVA USA
MFG#: 63459-0104-50
NDC: 63459-0104-50
PID: 421435
Additional Information
| Product Name | Truxima- Rituximab-Abbs Injection, Solution 500Mg/50Ml (10Mg/Ml) |
| Active Ingredient | Rituximab-abbs (biosimilar) |
| Mechanism of Action | Binds to CD20 on B cells, inducing cell death through cytotoxic and apoptotic pathways |
| Strength | 500 mg / 50 mL (10 mg/mL) |
| Route of Administration | Intravenous infusion |
| Common Side Effects | Infusion reactions, fever, chills, nausea, fatigue, rash |
| Serious Adverse Effects | Progressive multifocal leukoencephalopathy (PML), severe infections, tumor lysis syndrome, cardiac events |
| Monitoring Requirements | Complete blood count (CBC), renal function, infusion reaction symptoms, infection risk |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F), protect from light, do not freeze or shake |
| Packaging | 50 mL single-use vial |
| Uses | Non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA) |
Description
Truxima (rituximab-abbs) injection, solution 500 mg/50 mL (10 mg/mL), is a biosimilar monoclonal antibody targeting the CD20 antigen on B lymphocytes. It is indicated for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). By selectively depleting CD20-positive B cells, Truxima reduces malignant cell proliferation in hematologic cancers and modulates immune responses in autoimmune diseases.
The mechanism of action involves binding to CD20 antigens on B-cell surfaces, leading to cell destruction through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. This targeted B-cell depletion reduces disease progression in NHL and CLL while decreasing inflammation in autoimmune disorders.
Infusion-related reactions, including fever, chills, hypotension, and respiratory distress, are common, particularly during the initial infusion. Premedication with antihistamines, corticosteroids, and acetaminophen is recommended to reduce these effects. Severe adverse reactions include progressive multifocal leukoencephalopathy (PML), severe infections, tumor lysis syndrome, and cardiac complications.
Frequently Asked Questions (FAQs)
The cost of TRUXIMA- rituximab-abbs injection, solution 500mg/50mL (10mg/mL) is $available for registerd members only
TRUXIMA- rituximab-abbs injection, solution 500mg/50mL (10mg/mL) is manufactured by TEVA USA.
You can purchase TRUXIMA- rituximab-abbs injection, solution 500mg/50mL (10mg/mL) on our website at https://supplies.pipelinemedical.com/product/detail/truxima-10mg-ml-50ml-sdv-1-ea-421435